RxDoctor Payments Data

Jeffrey McDougall, MD

Family Medicine · Melbourne, FLNPI 1922089218

Payments from drug & device makers

$1,295in general payments, 2019–2025

Across 65 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$431
  • AstraZeneca$170
  • Sunovion Pharmaceuticals Inc.$121
  • Merck$96
  • Pfizer$87
  • E.r. Squibb & Sons, L.L.C.$71
  • plus $319 from 8 others

What the payments were for

  • Food & beverage$1,295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,295 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$126,164
Medicare patients
254
Services billed
3,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$71,299
JardianceEmpagliflozin50$56,086
XareltoRivaroxaban20$22,155
OzempicSemaglutide16$19,242
MyrbetriqMirabegron13$15,560
Valsartan156$6,454
Rosuvastatin Calcium230$5,968
Metoprolol Succinate202$4,406
Levothyroxine Sodium282$3,834
Lisinopril296$3,726
Atorvastatin Calcium225$3,500
Amlodipine Besylate360$3,305
Pravastatin Sodium180$3,146
Pantoprazole Sodium143$2,934
PaxlovidNirmatrelvir/Ritonavir16$2,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$87$74,09688 claims
Boehringer IngelheimJardiance$44$56,08650 claims
Novo NordiskOzempic$27$19,24216 claims
Astellas Pharma US IncMyrbetriq$63$15,56013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →